openPR Logo
Press release

Asthma and COPD Drugs market Key Players are GlaxoSmithKline, Novartis AG, Merck & Co., Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer.

02-22-2019 07:04 PM CET | Health & Medicine

Press release from: Allied Market Research

Asthma and COPD Drugs market Key Players are GlaxoSmithKline,

Asthma is a chronic respiratory disease blocking the airways of the lung because of inflammation, mucus production, tightening of muscles. Chronic Obstructive Pulmonary Disease(COPD) is caused by the obstruction in the airways causing difficulty in breathing, with the primary cause as tobacco smoking.

Get the Sample Report: https://www.alliedmarketresearch.com/request-sample/311?utm_source=openpr&utm_medium=Niranjan

Global COPD and asthma devices market is expected to reach $41,355.2 million by 2022, according to a new report by Allied Market Research. The drug powder inhaler was the highest revenue-generating segment, accounting for over half of the share in 2015. This segment is expected to maintain its dominance throughout the forecast period.

The factors hampering the market growth include environmental concerns associated with metered dose inhalers (MDI) and the high cost of selected inhalation devices. Regulatory authorities such as U.S. food and drug administration (USFDA) across several regions have banned the production and sales of MDIs, as they release environmentally hazardous gases such as a chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA). Thus, soft mist inhalers (SMIs) and nebulizers are expected to replace MDIs for the treatment of respiratory diseases in the near future.

Compressor nebulizers constitute around four-fifths share of the overall nebulizers market, owing to their perpetual usage in home healthcare medication and widespread availability across various regions. Nebulizers are electric- or battery-powered machines, which dispense the medication in the form of fine mist. They are used in home healthcare set-ups for debilitated patients, geriatric, and children. However, the large size of nebulizers and the need for continuous power supply are expected to hinder the market growth.

For Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/311?utm_source=openpr&utm_medium=Niranjan

Key findings of COPD and Asthma Devices Market:
- Drug powder inhalers (DPIs) segment is projected to grow at a significant CAGR of 5.7% during the forecast period.

- North America was the leading region in 2015 and is expected to continue its dominance throughout the analysis period.

- The COPD and asthma devices market in Europe is projected to grow at a CAGR of 6.1%.

- The compressor nebulizers segment is expected to register a CAGR of 5.4%.

- North America is expected to remain the highest revenue-generating region, owing to widespread and early adoption of inhalers & nebulizers and a large pool of patients suffering from respiratory diseases.

- Moreover, the Asia-Pacific region is expected to grow rapidly due to rising healthcare expenditure, growing awareness of advanced portable COPD & asthma devices, and increasing disposable income.

The key product manufacturing companies profiled in this report include - - --- GlaxoSmithKline Plc
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca Plc
- Philips Healthcare
- 3M Health Care
- Allied Healthcare Products, Inc.
- Sunovion Pharmaceuticals, Inc.
- GF Healthcare Products
- Smith Medicals, Inc.
- Lincare Holdings, Inc
- Baxter International.

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Asthma and COPD Drugs market Key Players are GlaxoSmithKline, Novartis AG, Merck & Co., Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer. here

News-ID: 1611222 • Views:

More Releases from Allied Market Research

Surface Computing Market Sustaining a Robust CAGR of 33.8% From 2023-2032
Surface Computing Market Sustaining a Robust CAGR of 33.8% From 2023-2032
According to a new report published by Allied Market Research, titled, "Surface Computing Market, by Component (Hardware, Software), by Display Type (Flat Display, Curved Display), by Industry Vertical (Healthcare, BFSI, Automotive, Hospitality, Retail, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032" The surface computing market was valued at $42.5 billion in 2022, and is estimated to reach $762.1 billion by 2032, growing at a CAGR of 33.8% from 2023 to 2032. Download
Why Invest in Prescriptive Analytics Market Which Size Reach USD 12.35 Billion By 2026
Why Invest in Prescriptive Analytics Market Which Size Reach USD 12.35 Billion B …
According to the report published by Allied Market Research, Why Invest in Prescriptive Analytics Market Which Size Reach USD 12.35 Billion By 2026. The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers valuable able guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining a competitive edge in the market. Surge in
Electric wheelchair market is expected to exceed $6.8 billion by the end of 2030
Electric wheelchair market is expected to exceed $6.8 billion by the end of 2030
According to a new report published by Allied Market Research, titled, "Electric Wheelchair Market by Type: Opportunity Analysis and Industry Forecast, 2021-2030," the electric wheelchair market was valued at $2.7 billion in 2020, and is projected reach $6.8 billion by 2030, registering a CAGR of 8.4% from 2021 to 2030 The global electrical wheelchairs market has witnessed notable growth in the last few years, owing to increase in trend of automation
Why Invest in USD 1.08 Trillion Internet Advertising Market Which Reach by 2027 at 17.2% CAGR
Why Invest in USD 1.08 Trillion Internet Advertising Market Which Reach by 2027 …
According to the report published by Allied Market Research "Why Invest in USD 1.08 Trillion Internet Advertising Market Which Reach by 2027 at 17.2% CAGR." These players have adopted different strategies such as new product launches collaborations expansion joint ventures agreements and others to increase their market share and maintain dominant shares in different regions. Increase in adoption of smartphones, emergence of high speed internet, proliferation of social media, growing

All 5 Releases


More Releases for COPD

Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's. It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be
COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858 The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the
04-10-2017 | Health & Medicine
TMR
Asthma and COPD Drugs Market: High Costs of Asthma and COPD Drugs and Consumer A …
Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the